The typical job of the proteasome, the garbage disposal of the cell, is to grind down proteins into smaller bits and recycle some of those bits and parts. That's still the case, for the most part, but, Johns Hopkins Medicine ...
Apr 12, 2024
0
67
A new research paper titled "GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells" has been published in Oncotarget.
Mar 6, 2024
0
0
The waste system of living cells, the proteasome, not only shreds disused or damaged proteins, it also supports the immune system by recognizing virally infected or cancerous cells by producing protein fragments, so-called ...
Feb 14, 2024
0
55
Structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers ...
Jan 18, 2024
0
7
Proteasomes are protein-degrading complexes that are important for cancer cell survival. Proteasome inhibitors are commonly used to treat diseases such as multiple myeloma and mantle cell lymphoma. Proteasomes have three ...
Dec 14, 2023
0
15
Smart users of social media protect themselves by deleting suspicious "friend requests" that might serve as a gateway to harmful content. Similarly, our immune system uses its own judgment to identify cellular "profiles" ...
Sep 20, 2023
0
26
The U.S. Food and Drug Administration has approved Talvey (talquetamab-tvgs) for patients with relapsed or refractory multiple myeloma.
Aug 16, 2023
0
1
Cold activates a cellular cleansing mechanism that breaks down harmful protein aggregations responsible for various diseases associated with aging. In recent years, studies on different model organisms have already shown ...
Apr 3, 2023
0
344
When Yoni Silverman, now 13, was a toddler, his parents fretted as he missed milestone after milestone. The New York City couple took their son to a host of specialists, searching for answers about why he wasn't speaking ...
Mar 16, 2023
0
4
Multiple myeloma is a type of cancer that affects plasma cells, the blood cells involved in the production of antibodies. It is the second most common hematologic cancer, accounting for 2% of all cancers of hematologic origin.
Nov 9, 2022
0
14
